Table 2.

Distribution of the number of patients with CMV reactivation (≥ 3 log₁₀ IU/ml) over the study periods.

Follow-up	CMV reactivation n (%) [95% CI]
D0–M6	14 (21.9%) [12.5; 34.0]
D0–M12	19 (29.7%) [18.9; 42.4]
M1–M4	11 (17.2%) [8.9; 28.7]
M1–M6	14 (21.9%) [12.5; 34.0]
M1–M12	19 (29.7%) [18.9; 42.4]